×
About 81,376 results

ALLMedicine™ Ovarian Cancer Center

Research & Reviews  37,845 results

The Prognostic and Diagnostic Potential of Kallikrein-Related Peptidases in Ovarian Can...
https://doi.org/10.1080/14737159.2021.1924680
Expert Review of Molecular Diagnostics; Riedel M, Bronger H et. al.

May 5th, 2021 - Ovarian cancer is one of the deadliest malignancies among women worldwide. The lack of early diagnostic markers fuels an unfavorable prognosis as most patients are at an advanced stage when the disease is diagnosed for the first time. The role of ...

Dietary Vitamin K Intake and the Risk of Pancreatic Cancer: A Prospective Study of 1016...
https://doi.org/10.1093/aje/kwab131
American Journal of Epidemiology; Yu DW, Li QJ et. al.

May 5th, 2021 - No epidemiological studies have been conducted to assess the association of dietary vitamin K intake with the risk of pancreatic cancer. We used prospective data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial between 1993 ...

Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
https://doi.org/10.1186/s12885-021-08233-5 10.3322/caac.21492 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5 10.1038/s41591-019-0407-5 10.1001/jamaoncol.2016.2129 10.1158/1078-0432.CCR-12-1796 10.1016/j.ygyno.2016.04.533 10.1158/1078-0432.CCR-14-1814 10.1016/j.ygyno.2012.04.006 10.1016/j.ygyno.2016.12.002 10.1038/nature10166 10.1097/IGC.0000000000000677 10.1038/modpathol.2013.107 10.1158/0008-5472.CAN-04-2933 10.1016/j.humpath.2006.10.007 10.2353/ajpath.2009.081000 10.1016/j.ygyno.2016.11.045 10.1186/1755-8794-5-47 10.1016/j.gore.2017.02.007 10.1038/ncomms4156 10.18632/oncotarget.13456 10.1093/bioinformatics/btu436 10.1186/1471-2164-15-732 10.1038/s43018-020-0067-x 10.1200/JCO.2014.56.2728 10.1056/NEJMoa1506859 10.1158/2159-8290.CD-14-0849 10.1002/emmm.200900041 10.1093/carcin/bgs393 10.1038/onc.2013.311 10.18632/oncotarget.10308 10.1158/0008-5472.CAN-06-0140 10.1016/j.ygyno.2016.01.004 10.1158/0008-5472.CAN-09-4716 10.1200/JCO.2013.50.5669 10.1016/j.ygyno.2007.11.029 10.1200/JCO.2009.22.3354 10.1093/annonc/mds282 10.1200/JCO.2014.55.7348 10.2217/whe.16.4 10.5732/cjc.014.10289 10.1126/science.1162981 10.1158/1535-7163.MCT-13-0639 10.1016/j.molmed.2010.05.001 10.1038/nrurol.2015.206 10.1038/onc.2015.125 10.1158/1078-0432.CCR-14-0947 10.18632/oncotarget.27251 10.1016/j.ygyno.2011.06.022 10.3892/ijo.2015.2951 10.1016/j.ygyno.2020.02.011 10.1038/nrd4281 10.1038/d41573-019-00195-5 10.1038/nrc.2016.138 10.18632/oncotarget.24585 10.1097/GCO.0000000000000243 10.1158/1078-0432.CCR-11-2509 10.1002/(SICI)1096-9896(200004)190:5<564::AID-PATH569>3.0.CO;2-L 10.1080/02841860410018548 10.1200/JCO.2011.39.8545 10.1056/NEJMoa1008433 10.1016/j.ebiom.2019.11.017 10.1158/1078-0432.CCR-13-2287 10.1002/ijc.32143 10.1056/NEJMoa1611310 10.1016/S1470-2045(16)30559-9 10.1016/j.bbcan.2018.07.005 10.1097/PAS.0b013e3182889dc3 10.1038/s41467-020-16416-0 10.1038/ncomms3578 10.1038/ejhg.2008.111 10.4137/CIN.S10176 10.1371/journal.pgen.1002103 10.1158/2159-8290.CD-12-0361 10.1038/ng.556 10.1038/s41568-019-0116-x 10.1186/s13073-017-0424-2 10.1158/0008-5472.CAN-12-1726 10.1016/j.celrep.2013.12.035 10.1038/nature13948 10.1158/1535-7163.MCT-13-0865 10.18632/oncotarget.7234 10.1016/S1470-2045(12)70572-7 10.1016/j.gore.2020.100547 10.1007/s10689-020-00184-3 10.1016/j.ccell.2014.11.006 10.1093/annonc/mdx784 10.1200/JCO.2018.36.15_suppl.1068 10.1016/j.ccell.2015.02.001 10.1038/nm.3613
BMC Cancer; Lapke N, Chen CH et. al.

May 5th, 2021 - Genetic alterations for epithelial ovarian cancer are insufficiently characterized. Previous studies are limited regarding included histologies, gene numbers, copy number variant (CNV) detection, and interpretation of pathway alteration patterns o...

Molecular and clinical determinants of response and resistance to rucaparib for recurre...
https://doi.org/10.1038/s41467-021-22582-6 10.1158/2159-8290.CD-15-0714 10.1177/1758835918778483 10.1158/1078-0432.CCR-13-2287 10.18632/oncotarget.17005 10.1016/S1470-2045(16)30376-X 10.1200/JCO.18.02238 10.1016/S0140-6736(17)32440-6 10.1056/NEJMoa1909707 10.1056/NEJMoa1910962 10.1056/NEJMoa1911361 10.1056/NEJMoa1706450 10.1056/NEJMoa1802905 10.1056/NEJMoa1903387 10.1056/NEJMoa1506859 10.1056/NEJMoa1911440 10.1158/1078-0432.CCR-20-0394 10.1158/2159-8290.CD-17-0419 10.1038/ncomms3578 10.1007/s10689-016-9919-z 10.1016/j.ygyno.2019.04.205 10.1371/journal.pgen.1006853 10.1038/nature10166 10.1016/j.ygyno.2016.08.328 10.1038/s41467-018-05564-z 10.1038/s41591-018-0009-7 10.1158/1078-0432.CCR-16-2615 10.1038/bjc.2012.451 10.1038/nm.4292 10.1038/ng.3934 10.1016/j.cell.2012.04.024 10.1016/j.ccell.2018.06.008 10.1038/nature17676 10.1038/s41588-018-0179-8 10.1158/1078-0432.CCR-15-2477 10.1186/bcr3670 10.1016/S1470-2045(16)30559-9 10.1158/2159-8290.CD-18-0715 10.1016/j.ygyno.2017.08.022 10.1200/JCO.2016.34.15_suppl.5540 10.1158/2159-8290.CD-17-0261 10.1038/nature14410 10.1038/s41416-018-0268-6 10.1002/path.2696 10.1073/pnas.1314302110 10.1158/1078-0432.CCR-14-1292 10.1016/j.ygyno.2016.08.320 10.1097/PAS.0000000000000958 10.1016/j.ygyno.2009.03.001 10.1200/JCO.20.01164 10.3892/or.2012.2041 10.1158/0008-5472.CAN-16-0186 10.1016/j.cell.2010.03.012 10.1016/j.ygyno.2019.01.015 10.1172/JCI70196 10.1158/1535-7163.MCT-17-0256 10.1073/pnas.1305170110 10.1038/s41467-019-09312-9 10.1056/NEJMoa2022485 10.1007/s10549-013-2693-9 10.1016/j.ygyno.2017.12.004 10.1016/S1470-2045(19)30029-4 10.2353/ajpath.2010.090780 10.1186/s12885-016-2598-1 10.1056/NEJMoa1810858 10.1038/sj.bjc.6602678 10.1038/nbt.2696 10.1371/journal.pcbi.1005965 10.1371/journal.pone.0140712 10.1016/j.jmoldx.2018.05.004 10.1371/journal.pone.0153844
Nature Communications; Swisher EM, Kwan TT et. al.

May 4th, 2021 - ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and R...

see more →

Guidelines  233 results

Breastfeeding Challenges: ACOG Committee Opinion, Number 820.
https://doi.org/10.1097/AOG.0000000000004253
Obstetrics and Gynecology;

Jan 22nd, 2021 - Breastfeeding is associated with a decrease in a woman's risk of breast cancer, ovarian cancer, diabetes mellitus, and hypertensive heart disease. Breastfeeding initiation rates in the United States are increasing, and many women are aware of the ...

ESMO recommendations on predictive biomarker testing for homologous recombination defic...
https://doi.org/10.1016/j.annonc.2020.08.2102
Annals of Oncology : Official Journal of the European Soc... Miller RE, Leary A et. al.

Oct 2nd, 2020 - Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an oppor...

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
https://doi.org/10.1200/JCO.20.01924
Journal of Clinical Oncology : Official Journal of the Am... Tew WP, Lacchetti C et. al.

Aug 13th, 2020 - To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). Randomized, controlled, and open-labeled trials published from 2011 through 2...

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

see more →

Drugs  133 results see all →

Clinicaltrials.gov  40,655 results

The Prognostic and Diagnostic Potential of Kallikrein-Related Peptidases in Ovarian Can...
https://doi.org/10.1080/14737159.2021.1924680
Expert Review of Molecular Diagnostics; Riedel M, Bronger H et. al.

May 5th, 2021 - Ovarian cancer is one of the deadliest malignancies among women worldwide. The lack of early diagnostic markers fuels an unfavorable prognosis as most patients are at an advanced stage when the disease is diagnosed for the first time. The role of ...

Dietary Vitamin K Intake and the Risk of Pancreatic Cancer: A Prospective Study of 1016...
https://doi.org/10.1093/aje/kwab131
American Journal of Epidemiology; Yu DW, Li QJ et. al.

May 5th, 2021 - No epidemiological studies have been conducted to assess the association of dietary vitamin K intake with the risk of pancreatic cancer. We used prospective data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial between 1993 ...

Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
https://doi.org/10.1186/s12885-021-08233-5 10.3322/caac.21492 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5 10.1038/s41591-019-0407-5 10.1001/jamaoncol.2016.2129 10.1158/1078-0432.CCR-12-1796 10.1016/j.ygyno.2016.04.533 10.1158/1078-0432.CCR-14-1814 10.1016/j.ygyno.2012.04.006 10.1016/j.ygyno.2016.12.002 10.1038/nature10166 10.1097/IGC.0000000000000677 10.1038/modpathol.2013.107 10.1158/0008-5472.CAN-04-2933 10.1016/j.humpath.2006.10.007 10.2353/ajpath.2009.081000 10.1016/j.ygyno.2016.11.045 10.1186/1755-8794-5-47 10.1016/j.gore.2017.02.007 10.1038/ncomms4156 10.18632/oncotarget.13456 10.1093/bioinformatics/btu436 10.1186/1471-2164-15-732 10.1038/s43018-020-0067-x 10.1200/JCO.2014.56.2728 10.1056/NEJMoa1506859 10.1158/2159-8290.CD-14-0849 10.1002/emmm.200900041 10.1093/carcin/bgs393 10.1038/onc.2013.311 10.18632/oncotarget.10308 10.1158/0008-5472.CAN-06-0140 10.1016/j.ygyno.2016.01.004 10.1158/0008-5472.CAN-09-4716 10.1200/JCO.2013.50.5669 10.1016/j.ygyno.2007.11.029 10.1200/JCO.2009.22.3354 10.1093/annonc/mds282 10.1200/JCO.2014.55.7348 10.2217/whe.16.4 10.5732/cjc.014.10289 10.1126/science.1162981 10.1158/1535-7163.MCT-13-0639 10.1016/j.molmed.2010.05.001 10.1038/nrurol.2015.206 10.1038/onc.2015.125 10.1158/1078-0432.CCR-14-0947 10.18632/oncotarget.27251 10.1016/j.ygyno.2011.06.022 10.3892/ijo.2015.2951 10.1016/j.ygyno.2020.02.011 10.1038/nrd4281 10.1038/d41573-019-00195-5 10.1038/nrc.2016.138 10.18632/oncotarget.24585 10.1097/GCO.0000000000000243 10.1158/1078-0432.CCR-11-2509 10.1002/(SICI)1096-9896(200004)190:5<564::AID-PATH569>3.0.CO;2-L 10.1080/02841860410018548 10.1200/JCO.2011.39.8545 10.1056/NEJMoa1008433 10.1016/j.ebiom.2019.11.017 10.1158/1078-0432.CCR-13-2287 10.1002/ijc.32143 10.1056/NEJMoa1611310 10.1016/S1470-2045(16)30559-9 10.1016/j.bbcan.2018.07.005 10.1097/PAS.0b013e3182889dc3 10.1038/s41467-020-16416-0 10.1038/ncomms3578 10.1038/ejhg.2008.111 10.4137/CIN.S10176 10.1371/journal.pgen.1002103 10.1158/2159-8290.CD-12-0361 10.1038/ng.556 10.1038/s41568-019-0116-x 10.1186/s13073-017-0424-2 10.1158/0008-5472.CAN-12-1726 10.1016/j.celrep.2013.12.035 10.1038/nature13948 10.1158/1535-7163.MCT-13-0865 10.18632/oncotarget.7234 10.1016/S1470-2045(12)70572-7 10.1016/j.gore.2020.100547 10.1007/s10689-020-00184-3 10.1016/j.ccell.2014.11.006 10.1093/annonc/mdx784 10.1200/JCO.2018.36.15_suppl.1068 10.1016/j.ccell.2015.02.001 10.1038/nm.3613
BMC Cancer; Lapke N, Chen CH et. al.

May 5th, 2021 - Genetic alterations for epithelial ovarian cancer are insufficiently characterized. Previous studies are limited regarding included histologies, gene numbers, copy number variant (CNV) detection, and interpretation of pathway alteration patterns o...

Molecular and clinical determinants of response and resistance to rucaparib for recurre...
https://doi.org/10.1038/s41467-021-22582-6 10.1158/2159-8290.CD-15-0714 10.1177/1758835918778483 10.1158/1078-0432.CCR-13-2287 10.18632/oncotarget.17005 10.1016/S1470-2045(16)30376-X 10.1200/JCO.18.02238 10.1016/S0140-6736(17)32440-6 10.1056/NEJMoa1909707 10.1056/NEJMoa1910962 10.1056/NEJMoa1911361 10.1056/NEJMoa1706450 10.1056/NEJMoa1802905 10.1056/NEJMoa1903387 10.1056/NEJMoa1506859 10.1056/NEJMoa1911440 10.1158/1078-0432.CCR-20-0394 10.1158/2159-8290.CD-17-0419 10.1038/ncomms3578 10.1007/s10689-016-9919-z 10.1016/j.ygyno.2019.04.205 10.1371/journal.pgen.1006853 10.1038/nature10166 10.1016/j.ygyno.2016.08.328 10.1038/s41467-018-05564-z 10.1038/s41591-018-0009-7 10.1158/1078-0432.CCR-16-2615 10.1038/bjc.2012.451 10.1038/nm.4292 10.1038/ng.3934 10.1016/j.cell.2012.04.024 10.1016/j.ccell.2018.06.008 10.1038/nature17676 10.1038/s41588-018-0179-8 10.1158/1078-0432.CCR-15-2477 10.1186/bcr3670 10.1016/S1470-2045(16)30559-9 10.1158/2159-8290.CD-18-0715 10.1016/j.ygyno.2017.08.022 10.1200/JCO.2016.34.15_suppl.5540 10.1158/2159-8290.CD-17-0261 10.1038/nature14410 10.1038/s41416-018-0268-6 10.1002/path.2696 10.1073/pnas.1314302110 10.1158/1078-0432.CCR-14-1292 10.1016/j.ygyno.2016.08.320 10.1097/PAS.0000000000000958 10.1016/j.ygyno.2009.03.001 10.1200/JCO.20.01164 10.3892/or.2012.2041 10.1158/0008-5472.CAN-16-0186 10.1016/j.cell.2010.03.012 10.1016/j.ygyno.2019.01.015 10.1172/JCI70196 10.1158/1535-7163.MCT-17-0256 10.1073/pnas.1305170110 10.1038/s41467-019-09312-9 10.1056/NEJMoa2022485 10.1007/s10549-013-2693-9 10.1016/j.ygyno.2017.12.004 10.1016/S1470-2045(19)30029-4 10.2353/ajpath.2010.090780 10.1186/s12885-016-2598-1 10.1056/NEJMoa1810858 10.1038/sj.bjc.6602678 10.1038/nbt.2696 10.1371/journal.pcbi.1005965 10.1371/journal.pone.0140712 10.1016/j.jmoldx.2018.05.004 10.1371/journal.pone.0153844
Nature Communications; Swisher EM, Kwan TT et. al.

May 4th, 2021 - ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and R...

see more →

News  2,443 results

BRCA1/2 Mutations Raise Risk for Endometrial Cancer, Too
https://www.medscape.com/viewarticle/948530

Apr 1st, 2021 - NEW YORK (Reuters Health) - Women with a BRCA1 or BRCA2 mutation have an increased risk for endometrial cancer (EC), and the greatest risk is for the rare subgroup of serous-like and p53-abnormal endometrial cancers in BRCA1 mutation carriers, acc...

Cytoreduction in Advanced Ovarian Cancer: 'Keep the Status Quo'
https://www.medscape.com/viewarticle/948395

Mar 29th, 2021 - Cytoreductive surgery should be considered for advanced ovarian cancer even if patients do not respond to chemotherapy, according to researchers. A retrospective, case-control study showed that optimal cytoreductive surgery is an independent predi...

NICE Recommends Ovarian Cancer combination Option on Cancer Drugs Fund
https://www.medscape.com/viewarticle/948166

Mar 25th, 2021 - NICE has published draft guidance which recommends olaparib plus bevacizumab for use within the Cancer Drugs Fund (CDF) as an option for maintenance treatment of advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or p...

Rock Musician Turned Med Student Takes Aim at Ovarian Cancer
https://www.medscape.com/viewarticle/947871

Mar 21st, 2021 - When Stephen Harris first met Guns N' Roses, they were unknown and penniless, backing up The Cult on tour. "I used to steal alcohol from our dressing room for them and get them extra guest passes so they could sell them for money," he says. "Once ...

Risk-Reducing Salpingo-Oophorectomy Could Curb Breast Cancer
https://www.medscape.com/viewarticle/947109

Mar 10th, 2021 - NEW YORK (Reuters Health) - In women with pathogenic variants in BRCA1 and BRCA2, risk-reducing salpingo-oophorectomy (RRSO) to help avoid ovarian cancer also appears to reduce breast-cancer risk, particularly within five years of surgery, accordi...

see more →

Patient Education  67 results see all →